News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • U.S. and Iran nearing a deal to swap about $20 billion in frozen assets for enriched uranium, reducing regional escalation risk.
  • British stocks fell as oil names slid amid Middle East uncertainty while the pound held firm.
  • Colombian President Gustavo Petro will visit Caracas on April 24 to pursue talks with interim Venezuelan leader Delcy Rodriguez.
  • BYD applied to join the European Automobile Manufacturers' Association as its first Hungarian factory begins mass production.
  • Orange and Bouygues shares slid after a higher bid for SFR raised antitrust and deal-duration concerns.
  • Mizuho raised expectations for Broadcom, citing expanding custom AI chip deals and higher near-term AI revenue forecasts.

Latest Articles

BofA Lifts DigitalOcean Target to $72, Citing Agentic AI Tailwinds

BofA Lifts DigitalOcean Target to $72, Citing Agentic AI Tailwinds

BofA Securities raised its price target on DigitalOcean (DOCN) to $72 from $60 and maintained a Buy rating, pointing to accelerating interest in agentic AI frameworks such as Clawdbot and the company's positioning to host always-on inferencing workloads. The move follows strong recent price performance and positive operational signals, including qu…

BofA Cuts Teladoc Price Target to $7, Cites Mixed Segment Outlook

BofA Cuts Teladoc Price Target to $7, Cites Mixed Segment Outlook

BofA Securities reduced its target on Teladoc Health to $7 from $7.50 while keeping a Neutral rating, citing continued uncertainty in the company’s BetterHelp and Chronic Care segments. The firm lowered its valuation multiple to 4.1x calendar year 2026 EBITDA and noted flat sequential BetterHelp user growth alongside weaker year-over-year trends. T…

Golden Dome Missile Shield Hits First Anniversary With Limited Visible Progress

Golden Dome Missile Shield Hits First Anniversary With Limited Visible Progress

One year after the executive order creating the Golden Dome missile-defense initiative, the program has spent little of the $25 billion appropriated and remains stalled while officials and industry stakeholders debate classified elements of its space-based architecture. Small prototype contracts have been awarded, but major procurement and broad fu…

Canada’s IPO pipeline looks set to reopen in 2026 as market sentiment improves

Canada’s IPO pipeline looks set to reopen in 2026 as market sentiment improves

After roughly four years of subdued initial public offering activity, Canada’s primary equity market is showing signs of revival for 2026. Market participants say high interest rates and inflation, regulatory friction, and other headwinds kept many firms out of the public markets, but recent equity market strength and a sizable October deal have en…

Pfizer at $26 Looks Like a Setup, Not a Surrender

Pfizer at $26 Looks Like a Setup, Not a Surrender

Pfizer is trading around $25.88 with improving momentum and a 6.65% dividend yield. Even as the market debates big-picture healthcare policy shifts, PFE’s valuation looks compressed versus its cash generation profile and the stock is building a base just under the 52-week high. This trade idea targets a measured breakout with defined risk, leaning …

TD Cowen Starts Coverage on Zimmer Biomet, Assigns Buy and $109 Target

TD Cowen Starts Coverage on Zimmer Biomet, Assigns Buy and $109 Target

TD Cowen has initiated coverage of Zimmer Biomet (NYSE: ZBH) with a Buy rating and a $109 price target, implying about 25% upside from the current share price of $87.32. The firm points to a stronger growth and profitability outlook, underpinned by a 71.6% gross profit margin and 5.5% revenue growth over the past 12 months, while noting prior execu…

TD Cowen Starts Coverage of Beta Bionics With Hold, Cites Modest Upside

TD Cowen Starts Coverage of Beta Bionics With Hold, Cites Modest Upside

TD Cowen initiated coverage of Beta Bionics (NASDAQ:BBNX) with a Hold rating and a $17.00 price target, noting solid early commercial traction for the iLet system but expressing concerns that projected revenue gains may not justify an outsized valuation. The firm highlighted strong recent top-line growth alongside signs of a potential slowdown in n…

TD Cowen Initiates Coverage of Stryker With Hold Rating, $387 Price Target

TD Cowen Initiates Coverage of Stryker With Hold Rating, $387 Price Target

TD Cowen began coverage of Stryker Corporation (NYSE: SYK) with a Hold rating and a $387 price target shortly before the company's upcoming earnings report. The firm praised Stryker's long run of organic growth and renewed focus on margins, while noting valuation metrics that present both potential upside and premium multiples. Recent corporate mov…